Novocure Limited · NASDAQ:NVCR
Novocure — Q4 2022 Earnings Presentation
16 slides from Novocure's earnings presentation, Feb 23, 2023
Slide 1: Novocure Q4 2022 results
novecure’ Novocure Q4 2022 results Thursday, February 23, 2023 . mee patientforward
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Q4 2022 highlights
novecure’ » LUNAR pivotal study met primary, overall survival endpoint * INNOVATE-3 pivotal study interim analysis completed * Completed enrollment in pivotal PANOVA-3 study » New data released from 2-THE-TOP and EF-31 pilot studies ° Finalized national reimbursement in France ° Approved and launche
Slide 4: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a robust intellectu
Slide 5: An established commercial business in GBM
an established commercial business in GBM 10 ACTIVE MARKETS SWEDEN FRANCE,{:\ GERMANY. CANADA, 5 @ @ M SWITZERLAND AUSTRIA sua UNITED STATES iaeREL WAPAN COVERED LIVES GLOBALLY 5,450 ACTIVE PATIENTS ON THERAPY AS OF DECEMBER 31, 2022 S538M FULL YEAR 2022 NET REVENUES patien tforward © 2023Novocure G
Slide 6: Growing body of real-world evidence supporting
novecure’ growing body of real-world evidence supporting Statistically significant improvements in OS CBTRUS Improvements in survival for glioblastoma in the post-Stupp protocol era uv Duke University Suieeghe ee School of Medicine Corey Neff2, Mackenzie Price'?, Gordon Chavez, Christina Proeschold,
Slide 7: To be presented at a future medical congress
A TO BE PRESENTED AT A FUTURE MEDICAL CONGRESS ‘Trial design can be found on www clinicaltrials gov. INCTO2973789}. 0S, overall survival.
Slide 8: Enrollment complete in pivotal PANOVA-3 study
novecure’ enrollment complete in pivotal PANOVA-S study Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of . . Tumor Treating Fields in Pancreatic f [ d Cimon eins our pivotal studies EXPECTED TO READOUT OVER THE NEXT TWO YEARS February 15.2023 an) LUNAR to PANOVA-3 Lung Cancer Pa
Slide 9: Platform technology driving robust clinical pipeline
novecure’ platform technology driving robust clinical pipeline TRIAL TTFIELDS + | APPROVED EF-14 temozolomide newly diagnosed TRIDENT. temozolomide + radiation CNS glioblastoma temozolomide + : KEYNOTE D58 program pembrolizumab gliobisstorna EF-L1 monotherapy ED brain metastasis METIS monotherapy th
Slide 10: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps In the first patient use, new arrays exhibited a improvement in field intensity in tumor region versus existing arrays patientforward © 2023Novocure GmbH 10 Acra
Slide 11: Q4 2022 selected financial highlights
q4 2022 selected financial highlights U.S. DOLLARS IN THOUSANDS Q4 2022 Q4 2021 % CHANGE Net revenues 128,429 $ 133,213 -4% Cost of revenues 28,888 29,687 -3% Gross profit 99,541 103,526 -4% Research, development and clinical trials 54,820 56,931 -4% Sales and marketing 49,629 38,982 27% General and
Slide 12: Together with our patients, we strive to extend survival
Slide 13: Optune Lua and Optune indications for use
novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS » Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of
Slide 14: Optune Lua and Optune indications for use
novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event
Slide 15: Appendix
novecure’ appendix patientforward
Slide 16: Adjusted EBITDA reconciliation
novocure adjusted EBITDA reconciliation Adjusted EBITDA is a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare